Edwards Lifesciences (NYSE:EW) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Edwards Lifesciences (NYSE:EW) from a buy rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $86.97 on Friday. The stock has a market cap of $50.08 billion, a P/E ratio of 49.99, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock’s fifty day moving average is $88.47 and its 200 day moving average is $86.02. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,503,375.34. This represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,045 shares of company stock worth $455,341. 0.31% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently modified their holdings of the stock. QRG Capital Management Inc. grew its stake in Edwards Lifesciences by 16.0% during the second quarter. QRG Capital Management Inc. now owns 69,999 shares of the medical research company’s stock valued at $6,332,000 after acquiring an additional 9,672 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Edwards Lifesciences by 53.7% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 5,092 shares of the medical research company’s stock worth $461,000 after purchasing an additional 1,778 shares in the last quarter. Andra AP fonden lifted its stake in Edwards Lifesciences by 49.0% in the 2nd quarter. Andra AP fonden now owns 171,269 shares of the medical research company’s stock worth $15,493,000 after purchasing an additional 56,300 shares in the last quarter. Tidal Investments LLC boosted its holdings in shares of Edwards Lifesciences by 2.1% during the 2nd quarter. Tidal Investments LLC now owns 104,368 shares of the medical research company’s stock valued at $9,441,000 after purchasing an additional 2,159 shares during the last quarter. Finally, Van Hulzen Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Van Hulzen Asset Management LLC now owns 35,500 shares of the medical research company’s stock valued at $3,211,000 after purchasing an additional 1,476 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.